BioVista PRE-LAUNCH · EARLY ACCESS

The biotech signals Bloomberg is too
big to notice.

Dilution detection wired into the FDA catalyst calendar. Insider buying cross-checked against rising short interest. Filings translated into plain English — across a deliberately fixed universe of 287 biotech names.

No spam · invites in waves · not investment advice

PRECISION OVER COVERAGE

Every terminal races to cover 8,000 tickers.
We chose 287.

Coverage is a vanity metric. The moment a tool tries to watch everything, it watches nothing well. BioVista tracks a fixed, hand-picked universe of clinical-stage and commercial biotech — deeply — so every signal actually means something.

Smaller and accurate beats large and wrong.

THE EVERYTHING TERMINAL 8,000+
THE BIOVISTA UNIVERSE 287

≈ 1 in 28 public biotechs makes the cut. The rest is noise we deliberately leave out.

WHAT YOU ACTUALLY GET

Three signals you won't find fused anywhere else.

Design tweaks dev preview only
Accent color